Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 92

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 92
---
 as a basis for point-of-care decision support devices. From February 2014 until April 2018, Inna Martin served as Investment Director at a Luxembourg based, a healthcare focused VC fund, partner of Domain Associates LLC (USA), where she managed portfolio companies in major innovation hubs including North America and Europe. In September 2018, she founded Seven Sons Ltd., Israel, a clinical stage medical device company, focusing on the development of Stent Positioning Assistance System, SPAS, a novel proprietary tool developed for safer PCI procedure and precise stent positioning.

Inna Martin received her MBA in 2000 fromBar Ilan University, Israel, her BA in English and Psychology in 1996 from

Orenburg State University, Russian Federation. In 2021, she received certification in Management Executive Education, Artificial Intelligence in Health Care from MIT, MA.

Arie Gordashnikov, 41, became the Company’s Chief Financial Officer. effective as of June I, 2023. He has over 13 years of experience in accounting, auditing and finance of Hi-Tech and biotechnology companies. Since 2018, he serves as Head of IPO & M&A Department at Shimony Yosef Certified Public Accountant (Israel) and has been providing accounting and financial advisory services to the Company since 2018. He very well knows company’s history, prepared all quarterly and annual reports, experienced in RCC and PCAOB reporting. Through his devoted work for several years for Revium, he has proven to be a devoted and diligent partner. Before joining Shimony CPA FIRM, from 2009 to 2017, Mr. Gordashnikov was an Audit Manager at Ernst & Young Israel. Mr. Gordashnikov holds an MBA degree from Tel Aviv University in financial management, a B.A. in Accounting and Economics from Hebrew University of Jerusalem and he has been a licensed CPA since 2012.

<div align='center'>56</div>

Bernard Bartal, 59, joined the Company as a director on June 2023, and since June 22, 2023, he serves as Chairman. He co-founded several technology companies, including Dien-A Mollecular Biology Ltd., a NGS technology company focused on significant elongation of DNA sequencing reads; Advanced Concepts in Biology LLC, focused on advanced gene expression technologies; Biotic Therapeutics Ltd., focused on anti-inflammatory polyphenol small molecules research.

Mr. Bartal received BS in 1990 in biology from Tel